Application Nr Approved Date Route Status External Links
NDA211230 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Sunosi Is Indicated To Improve Wakefulness In Adult Patients With Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea (Osa) [See Clinical Studies ( 14 )]. Limitations Of Use Sunosi Is Not Indicated To Treat The Underlying Airway Obstruction In Osa. Ensure That The Underlying Airway Obstruction Is Treated (E.g., With Continuous Positive Airway Pressure (Cpap)) For At Least One Month Prior To Initiating Sunosi For Excessive Daytime Sleepiness. Modalities To Treat The Underlying Airway Obstruction Should Be Continued During Treatment With Sunosi. Sunosi Is Not A Substitute For These Modalities. Sunosi Is A Dopamine And Norepinephrine Reuptake Inhibitor (Dnri) Indicated To Improve Wakefulness In Adult Patients With Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea (Osa). ( 1 ) Limitations Of Use Sunosi Is Not Indicated To Treat The Underlying Airway Obstruction In Osa. Ensure That The Underlying Airway Obstruction Is Treated (E.g., With Continuous Positive Airway Pressure (Cpap)) For At Least One Month Prior To Initiating Sunosi For Excessive Daytime Sleepiness. Modalities To Treat The Underlying Airway Obstruction Should Be Continued During Treatment With Sunosi. Sunosi Is Not A Substitute For These Modalities. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Solriamfetol

Comments